CXCR4 and endometrial cancer: The fact that most endometrial cancer (EC) patients overexpress the CXCR4 receptor in tumor tissue, especially at incurable advanced stages, opens an avenue for developing novel therapies targeting CXCR4+ EC cells to add new armamentarium against this malignancy.